Emerging therapies for residual risk

Reviews in Cardiovascular Medicine

Volumn 13, Issue 1, 2012, Pages

  Mehra, Sanjay ^a   Movahed, Hossein ^a   Movahed, Assad ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [(3,3' BITHIOPHEN 5 YL)METHOXY] N (6,6 DIMETHYL 2 HEPTEN 4 YNYL) N ETHYLBENZYLAMINE; ANACETRAPIB; BEZAFIBRATE; BILE ACID SEQUESTRANT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESEVELAM; DALCETRAPIB; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAPAQUISTAT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RESVERATROL; RO 48 8071; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; STEROL 14ALPHA DEMETHYLASE; TORCETRAPIB; TRIACYLGLYCEROL; TU 2208; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIARRHEA; DRUG FATALITY; DYSLIPIDEMIA; FLATULENCE; FLUSHING; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSULIN RESISTANCE; INTESTINE ABSORPTION; ISCHEMIC HEART DISEASE; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; STROKE; SUDDEN DEATH; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84863112182     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0583     Document Type: Review

References (68)

1. Ridker PM, Danielson E, Fonseca FA, et al JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
2. Nichols GA, Ambegaonkar BM, Sazonov V, Brown JB. Frequency of obtaining National Cholesterol Education Program Adult Treatment Panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. Am J Cardiol. 2009;104:1689-1694.
3. Israeli Society for the Prevention of Heart Attack. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21-27.
4. Goldenberg I, Boyko V, Tennenbaum A, et al. Longterm benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch Intern Med. 2009;169:508-514.
5. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517. (Pubitemid 39612564)
6. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest. 2007;117:746-756. (Pubitemid 46348533)
7. Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24:2181-2187. (Pubitemid 39482449)
8. Asztalos BF. High-density lipoprotein particles, coronary heart disease, and niacin. J Clin Lipidol. 2010;4:405-410.
9. Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis. 2010;213:1-7.
10. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847-870. (Pubitemid 44716510)
11. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006;113:20-29. (Pubitemid 43958484)
12. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002;106:1930-1937. (Pubitemid 35176297)
13. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-implications for LDL management. J Clin Lipidol. 2007;1:583-592. (Pubitemid 350215511)
14. Hsia J, Otvos JD, Rossouw JE, et al; for the Women's Health Initiative Research G. Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. Arterioscl Thromb Vasc Biol. 2008;28:1666-1671.
15. Sniderman AD. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. J Clin Lipidol. 2008:2:36-42. (Pubitemid 351250867)
16. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-1 trial. Atherosclerosis. 2002;160:41-48. (Pubitemid 34082715)
17. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-1) trial. Am J Cardiol. 2002;90:89-94. (Pubitemid 34775113)
18. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized control trial. JAMA. 2001;285:1585-1591. (Pubitemid 32240250)
19. Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/highdensity lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. JACC. 2010;55:35-41.
20. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201-1204. (Pubitemid 38233587)
21. Davis HR Jr, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279:33586-33592. (Pubitemid 39063007)
22. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102:8132-8137. (Pubitemid 40800055)
23. Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb. 2007;14:99-108.
24. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther. 2008;6:447-470.
25. Bays HE, Moore PB, Drehobl MA, et al Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001;23:1209-1230. (Pubitemid 32804115)
26. Dujovne CA, Ettinger MP, McNeer JF, et al Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092-1097. (Pubitemid 35335597)
27. Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943-1948. (Pubitemid 35176299)
28. Knopp RH, Gitter H, Truitt T, et al Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729-741. (Pubitemid 36458985)
29. Gagné C, Bays HE, Weiss SR, et al Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1084-1091. (Pubitemid 35339435)
30. Grigore L, Norata GD, Catapano AL. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vasc Health Risk Manag. 2008;4: 267-278. (Pubitemid 351711955)
31. Leiter LA, Bays H, Conard S. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol. 2008;102:1495-1501.
32. Stein EA. Low-density lipoprotein cholesterol reduction and prevention of cardiovascular disease. Mayo Clin Proc. 2009;84:307-309.
33. Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract. 2008;62:88-96. (Pubitemid 350294010)
34. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007;49:1753-1762. (Pubitemid 46617861)
35. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol. 2008;153(suppl 3):S68-S75. (Pubitemid 351340990)
36. Whayne TF Jr. High-density lipoprotein cholesterol: current perspective for clinicians. Angiology. 2009;60:644-649.
37. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55:2721-2726.
38. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786-798. (Pubitemid 47263161)
39. Kontush A, Guérin M, Chapman MJ. Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med. 2008;5: 329-336. (Pubitemid 351761707)
40. Huang Z, Inazu A, Nohara A, et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond). 2002;103:587-594. (Pubitemid 36005711)
41. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet. 2007;370: 1907-1914. (Pubitemid 350192656)
42. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352-360.
43. Cannon CP, Shah S, Dansky HM, et al Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-2415.
44. Barter PJ, Caulfield M, Eriksson M, et al ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122. (Pubitemid 350146106)
45. Hou R, Goldberg AC. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am. 2009;38:79-97.
46. Jacobson TA, Armani A, Mckenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol. 2007;99:47C-55C.
47. Bays H, Jones PH. Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vasc Health Risk Manag. 2007;3:733-742. (Pubitemid 350104127)
48. Melian EB, Plosker GL. Colesevelam. Am J Cardiovasc Drugs. 2001;1:141-146; discussion 147-148.
49. Palmer CN, Hsu MH, Griffin KJ, et al. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol. 1998;53:14-22. (Pubitemid 28068368)
50. Michalik L, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors beta/delta: emerging roles for a previously neglected third family member. Curr Opin Lipidol. 2003;14:129-135. (Pubitemid 36521182)
51. Brinton EA. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio? Curr Atheroscler Rep. 2008;10:25-32. (Pubitemid 351385596)
52. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30:1280-1287. (Pubitemid 35265837)
53. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002;301: 1042-1051. (Pubitemid 34595097)
54. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother. 2007;8:2569-2578. (Pubitemid 350031294)
55. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther. 2002;24:378-396. (Pubitemid 34275860)
56. Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther. 2003;25(suppl B): B64-B80. (Pubitemid 37072286)
57. Winkler K, Konrad T, Füllert S, et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a doubleblind, placebo-controlled study. Diabetes Care. 2003;26:2588-2594. (Pubitemid 37052104)
58. Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55:1885-1894.
59. Elsayed RK, Evans JD. Emerging lipid-lowering drugs: squalene synthase inhibitors. Expert Opin Emerg Drugs. 2008;13:309-322. (Pubitemid 351957350)
60. Chugh A, Ray A, Gupta JB. Squalene epoxidase as hypercholesterolemic drug target revisited. Prog Lipid Res. 2003;42:37-50. (Pubitemid 35428788)
61. Clarke GA, Bouchard G, Paigen B, Carey MC. Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse. Gut. 2004;53:136-142. (Pubitemid 38083022)
62. Korosec T, Acimovic J, Seliskar M, et al. Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14alpha-demethylase (CYP51). Bioorg Med Chem. 2008;16:209-221.
63. Berthois Y, Bourrié B, Galiègue S, et al. SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo. Br J Cancer. 2003;88:438-446. (Pubitemid 36308157)
64. AIM-HIGH: niacin plus statin to prevent vascular events. Clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00120289. Accessed January 31, 2012.
65. HPS2-THRIVE: a randomized trial of the long-term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant. Clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00461630. Accessed January 31, 2012.
66. Schwartz GC, Olsson AG, Ballantyne CM, et al; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158:896-901.e3.
67. Contois JH, McConnell JP, Sethi AA, et al AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices. Clin Chem. 2009;55:407-419.
68. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology foundation. Diabetes Care. 2008;31:811-822.